2.50
price up icon8.70%   0.20
after-market アフターアワーズ: 2.51 0.010 +0.40%
loading
前日終値:
$2.30
開ける:
$2.22
24時間の取引高:
5.60M
Relative Volume:
1.16
時価総額:
$561.83M
収益:
$95,000
当期純損益:
$-327.27M
株価収益率:
-1.1792
EPS:
-2.12
ネットキャッシュフロー:
$-239.25M
1週間 パフォーマンス:
-5.66%
1か月 パフォーマンス:
+47.93%
6か月 パフォーマンス:
+119.30%
1年 パフォーマンス:
+14.68%
1日の値動き範囲:
Value
$2.21
$2.52
1週間の範囲:
Value
$2.20
$2.635
52週間の値動き範囲:
Value
$0.8621
$2.80

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
名前
Allogene Therapeutics Inc
Name
セクター
Healthcare (1110)
Name
電話
(650) 457-2700
Name
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
職員
361
Name
Twitter
@AllogeneTx
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
2.50 516.88M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.87 116.01B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
781.60 80.33B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
740.40 44.42B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.59 42.53B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
302.29 33.32B 5.36B 287.73M 924.18M 2.5229

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-09 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-10-10 ダウングレード JP Morgan Neutral → Underweight
2025-05-14 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 再開されました Oppenheimer Outperform
2024-05-31 開始されました Piper Sandler Overweight
2024-01-05 ダウングレード Guggenheim Buy → Neutral
2024-01-05 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 開始されました Citigroup Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-21 開始されました Bernstein Mkt Perform
2023-01-24 アップグレード JP Morgan Neutral → Overweight
2023-01-06 アップグレード Robert W. Baird Neutral → Outperform
2022-12-12 ダウングレード BofA Securities Buy → Underperform
2022-08-10 ダウングレード Raymond James Outperform → Mkt Perform
2022-07-15 アップグレード Goldman Neutral → Buy
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-28 繰り返されました B. Riley Securities Buy
2021-10-20 開始されました Cowen Outperform
2021-10-08 ダウングレード Goldman Buy → Neutral
2021-10-08 ダウングレード Stifel Buy → Hold
2021-09-23 アップグレード Raymond James Mkt Perform → Outperform
2021-06-21 再開されました Jefferies Buy
2021-05-20 アップグレード Truist Hold → Buy
2021-05-14 開始されました B. Riley Securities Buy
2021-01-26 アップグレード Stifel Hold → Buy
2020-12-10 再開されました H.C. Wainwright Buy
2020-11-24 開始されました BofA Securities Buy
2020-10-23 開始されました RBC Capital Mkts Outperform
2020-06-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-29 繰り返されました H.C. Wainwright Buy
2020-05-19 アップグレード ROTH Capital Neutral → Buy
2020-05-15 アップグレード Guggenheim Neutral → Buy
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-05-14 ダウングレード SunTrust Buy → Hold
2020-04-13 開始されました SunTrust Buy
2020-03-13 開始されました H.C. Wainwright Buy
2020-03-05 開始されました Stifel Hold
2020-02-24 開始されました Berenberg Hold
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-11-04 開始されました Canaccord Genuity Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-05 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Neutral
2019-05-23 開始されました Stifel Hold
2019-03-29 開始されました Piper Jaffray Overweight
すべてを表示

Allogene Therapeutics Inc (ALLO) 最新ニュース

pulisher
09:00 AM

Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus - TradingView

09:00 AM
pulisher
Mar 06, 2026

Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN

Mar 06, 2026
pulisher
Mar 06, 2026

Quarterly Recap: Will Allogene Therapeutics Inc benefit from geopolitical trendsJuly 2025 Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 05, 2026

Allogene Therapeutics (ALLO) Expected to Announce Earnings on Thursday - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,132 Shares of Stock - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen - Yahoo Finance

Mar 03, 2026
pulisher
Mar 03, 2026

ALLO: Key clinical milestones and manufacturing advances position allogeneic cell therapy for broad impact - TradingView

Mar 03, 2026
pulisher
Mar 02, 2026

Allogene Therapeutics (NASDAQ: ALLO) files Form 144 for 7,132 RSU shares - Stock Titan

Mar 02, 2026
pulisher
Mar 02, 2026

Allogene Therapeutics signals breakthrough hope for severe autoimmune disease patients - Traders Union

Mar 02, 2026
pulisher
Mar 02, 2026

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update - GlobeNewswire

Mar 02, 2026
pulisher
Mar 02, 2026

Ideas Watch: Will Allogene Therapeutics Inc stock hit new highs in YEARMarket Trend Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Mar 02, 2026
pulisher
Mar 01, 2026

ALLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 01, 2026
pulisher
Feb 28, 2026

Primecap Management Co. CA Has $8.78 Million Stock Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat

Feb 28, 2026
pulisher
Feb 27, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Feb 27, 2026
pulisher
Feb 25, 2026

Allogene Therapeutics (NASDAQ:ALLO) Reaches New 1-Year HighHere's What Happened - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

FOMO Trade: Is Allogene Therapeutics Inc.’s ROE strong enoughGold Moves & Weekly Breakout Watchlists - mfd.ru

Feb 25, 2026
pulisher
Feb 24, 2026

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 10.3%Should You Buy? - MarketBeat

Feb 24, 2026
pulisher
Feb 23, 2026

Allogene Therapeutics2026 Funding Rounds & List of Investors - Tracxn

Feb 23, 2026
pulisher
Feb 22, 2026

Allogene Therapeutics (NASDAQ:ALLO) Raised to "Hold" at Wall Street Zen - MarketBeat

Feb 22, 2026
pulisher
Feb 19, 2026

Treasury Yields: Whats the fair value of Blend Labs Inc stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn

Feb 19, 2026
pulisher
Feb 19, 2026

Allogene Therapeutics Faces Financial Challenges Despite Industry Moves - StocksToTrade

Feb 19, 2026
pulisher
Feb 18, 2026

Allogene Therapeutics Teases April ALPHA3 Data as cema-cel Targets MRD+ LBCL in Remission - Yahoo Finance

Feb 18, 2026
pulisher
Feb 18, 2026

MSN Money - MSN

Feb 18, 2026
pulisher
Feb 18, 2026

ALLO: ALPHA-3 aims for a 25%-30% MRD clearance improvement in lymphoma, with pivotal data due in April - TradingView

Feb 18, 2026
pulisher
Feb 17, 2026

Arie Belldegrun details 5.8% Allogene (ALLO) stake via multiple entities - Stock Titan

Feb 17, 2026
pulisher
Feb 16, 2026

Allogene Therapeutics unveils plans for Virtual Oncology Summit - Traders Union

Feb 16, 2026
pulisher
Feb 16, 2026

Atomera Among 3 Promising Penny Stocks - simplywall.st

Feb 16, 2026
pulisher
Feb 15, 2026

Will Allogene Therapeutics Inc. stock outperform value stocks2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

Allogene Therapeutics (NASDAQ:ALLO) Cut to "Sell" at Wall Street Zen - MarketBeat

Feb 14, 2026
pulisher
Feb 13, 2026

Will Allogene Therapeutics Inc. benefit from geopolitical trendsQuarterly Portfolio Report & Fast Entry Momentum Alerts - mfd.ru

Feb 13, 2026
pulisher
Feb 13, 2026

ALLO PE Ratio & Valuation, Is ALLO Overvalued - Intellectia AI

Feb 13, 2026
pulisher
Feb 13, 2026

Follicular Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic - Barchart.com

Feb 13, 2026
pulisher
Feb 13, 2026

Aug Selloffs: Is Bank of Montreal on track to beat earningsPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn

Feb 13, 2026
pulisher
Feb 13, 2026

Dr. Chang (NASDAQ: ALLO) discloses 5.2% Allogene ownership stake - Stock Titan

Feb 13, 2026
pulisher
Feb 11, 2026

Will Allogene Therapeutics Inc. outperform small cap indexesEarnings Trend Report & AI Powered Trade Plan Recommendations - mfd.ru

Feb 11, 2026
pulisher
Feb 11, 2026

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Yahoo Finance

Feb 11, 2026
pulisher
Feb 10, 2026

Why Allogene Therapeutics Inc. stock could see breakout soonTreasury Yields & Stock Portfolio Risk Management - mfd.ru

Feb 10, 2026
pulisher
Feb 09, 2026

Aug Drivers: Will Allogene Therapeutics Inc stock hit new highs in YEAREarnings Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn

Feb 09, 2026
pulisher
Feb 07, 2026

Allogene Therapeutics Approaches a Defining Period for Its Platform - AD HOC NEWS

Feb 07, 2026
pulisher
Feb 06, 2026

Don't Ignore The Insider Selling In Allogene Therapeutics - 富途牛牛

Feb 06, 2026
pulisher
Feb 05, 2026

Allogene Therapeutics explores cell therapy trial at ASTCT meeting - Traders Union

Feb 05, 2026
pulisher
Feb 05, 2026

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewswire

Feb 05, 2026
pulisher
Feb 05, 2026

Allogene EVP Roberts sells $63,189 in stock, gains options By Investing.com - Investing.com Canada

Feb 05, 2026
pulisher
Feb 05, 2026

Allogene Therapeutics CEO Chang David D sells $171k in stock - Investing.com Canada

Feb 05, 2026
pulisher
Feb 05, 2026

Allogene EVP Roberts sells $63,189 in stock, gains options - Investing.com UK

Feb 05, 2026
pulisher
Feb 04, 2026

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Feb 04, 2026
pulisher
Feb 04, 2026

Allogene Therapeutics SVP sells $13k in stock By Investing.com - Investing.com South Africa

Feb 04, 2026
pulisher
Feb 04, 2026

Allogene Therapeutics (NASDAQ:ALLO) EVP Sells $63,189.00 in Stock - MarketBeat

Feb 04, 2026
pulisher
Feb 04, 2026

Allogene Therapeutics (NASDAQ:ALLO) CEO David Chang Sells 95,269 Shares - MarketBeat

Feb 04, 2026
pulisher
Feb 04, 2026

Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,549 Shares of Stock - MarketBeat

Feb 04, 2026
pulisher
Feb 04, 2026

Allogene Therapeutics (NASDAQ:ALLO) CFO Sells $42,241.76 in Stock - MarketBeat

Feb 04, 2026

Allogene Therapeutics Inc (ALLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$99.79
price up icon 1.41%
$29.53
price up icon 2.61%
$55.74
price up icon 6.13%
$102.16
price up icon 0.65%
$143.13
price up icon 2.14%
biotechnology ONC
$302.29
price up icon 0.39%
大文字化:     |  ボリューム (24 時間):